An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus

Area of Science:

• Microbiology
• Biotechnology
• Medical Science

Background:

• Antimicrobial resistance and biofilms pose significant challenges to treating bacterial infections.
• Conventional antimicrobial therapies are increasingly compromised by multi-drug resistant pathogens and biofilm formation.
• Novel therapeutic strategies, including the use of engineered microorganisms, are emerging.

Purpose of the Study:

• To genetically engineer Mycoplasma pneumoniae to express antibiofilm and bactericidal enzymes.
• To evaluate the efficacy of engineered M. pneumoniae in disrupting Staphylococcus aureus biofilms in a murine model.
• To demonstrate the potential of engineered microorganisms as a therapeutic approach for biofilm-related infections.

Main Methods:

• Genetic modification of Mycoplasma pneumoniae to attenuate virulence and enable enzyme secretion.
• In vivo implantation of infected catheters in mice.
• Assessment of biofilm disruption and bacterial load reduction.

Main Results:

• Engineered M. pneumoniae successfully reduced the virulence of Staphylococcus aureus biofilms on implanted catheters in mice.
• The modified bacteria demonstrated antibiofilm and bactericidal activity in a relevant in vivo model.
• This study validates the use of genetically engineered bacteria as a potential therapeutic strategy.

Conclusions:

• Genetically engineered microorganisms offer a promising new avenue for combating challenging bacterial infections.
• The strategy of engineering M. pneumoniae to secrete therapeutic enzymes presents a viable approach for biofilm eradication.
• Further research into engineered microbial therapies could lead to effective treatments for multi-drug resistant infections.